CORRESP Filing
Tyra Biosciences, Inc.
Date: May 14, 2025 · CIK: 0001863127 · Accession: 0001193125-25-119821
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287086
Letter
Re: Tyra Biosciences, Inc. Registration Statement on Form S-3 File No. 333-287086 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Tyra Biosciences, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 16, 2025, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 May 14, 2025 VIA EDGAR Jason Drory Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
TYRA BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 May 14, 2025 VIA EDGAR Jason Drory Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Tyra Biosciences, Inc. Registration Statement on Form S-3 File No. 333-287086 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Tyra Biosciences, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 16, 2025, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter. Sincerely, TYRA BIOSCIENCES, INC. By: /s/ Alan Fuhrman Alan Fuhrman Chief Financial Officer cc: Todd Harris, Ph.D., Tyra Biosciences, Inc. Matthew T. Bush, Latham & Watkins LLP